This page summarises and signposts to medicine related guidance we’re aware of from professional and government bodies relating to coronavirus and family planning.
This page has been put together rapidly in response to the COVID-19 pandemic.
Whilst we have tried to ensure that the information on this page is complete, please report a concern if you feel anything is omitted or inaccurate.
To see our professional guidance summaries for other clinical areas, click here
Advice in this area includes:
The Faculty of Sexual & Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists: Clinical advice to support provision of effective contraception during the COVID-19 outbreak
Last updated: 20th March
- Existing users of combined hormonal contraception (CHC) can receive extended treatment for 6-12 months without checking BMI /blood pressure via a remote prescription.
- Existing users of a progesterone only pill (POP) can receive a further 12 month supply without a review. PGDs should be considered for supply by non-prescribers.
- Women currently using Depo Provera as a method of contraception should be switched to the POP.
- Women currently using Sayana Press as a method of contraception should continue to self-administer at home and can receive up to a 12 month supply.
- The use of copper IUDs cannot be extended beyond their license. Women will need to use an alternative form of contraception. However there is no need to remove them unless users want to become pregnant.
- Individuals requesting to start contraception should initially be offered a POP remotely. If a POP is not suitable second line options include a CHC or LARC method (if more suitable due to poor adherence or other teratogenic medicines).
- Consultations for emergency oral contraception should be done remotely. Delivery of medicines would not be suitable due to risk of possible delays in treatment.
The Faculty of Sexual & Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists: Recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions
Last updated: 20th March
- Replacement can be delayed for up to a year after expiry of both the etongestrel implant and 52mg levongestrel-releasing intrauterine system to avoid unnecessary risk of coronavirus transmission due to contact with healthcare professionals.
- Etongestrel implant can be used for up to four years.
- Levongestrel-releasing intrauterine system (52mg) can be used for up to six years.
The Faculty of Sexual & Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists: Information to support management of individuals requesting to discontinue contraception to plan a pregnancy during the Covid-19 outbreak
Last updated: 26th March
- Women planning a pregnancy who are currently using a LARC method of contraception will require face to face contact with a healthcare professional to have this removed.
The Faculty of Sexual & Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists: Position Restoration of SRH Services during Covid-19 and Beyond
Last updated: 5th June
- Guidance has been released relating to the restoration of sexual health services.
- There are two recovery phases with information how to restart LARC, monitoring of the COC, managing the menopause as well as contraception postpartum.
Administration update (24th August 2020): administrative amendments made to the page only.